CoupledCAR-T Therapy for Colorectal and Prostate Cancer
CoupledCAR-T Therapy for Colorectal and Prostate Cancer
Project profile curated by GlobalReach Link. Applications are reviewed on a rolling basis.
Stage: SeedRegion: Mainland ChinaIndustry: HealthTechOpen Status: OpenConfidential (NDA): Yes
Project Overview
A first-in-class CAR-T therapy platform targeting solid tumors, demonstrating 50–80% ORR in late-stage colorectal cancer patients across China and the U.S., with fast-track FDA approval and global market potential.
Project Goals
Fund Stage:Growth Stage
Raise Size:USD 1M to 3M
Investment Type:Equity
Skills Needed
This project is particularly suited to experts and teams with the following capabilities:
Financial Advisor / CPA
Legal / Solicitor (Cross-border)
Investment Consultant / Fundraising
Project Management
Competitive Advantage
• First CAR-T platform globally with strong efficacy in solid tumors (up to 80% ORR)
• Fully automated, high-yield manufacturing with 100% success rate
• Multi-indication pipeline under same CoupledCAR® platform
• Collaborations with top clinical centers: UCSF, Harvard Dana-Farber, COH, University of Colorado
Reasons to Invest & Market Opportunity
Reasons to Invest:
• Breakthrough CoupledCAR® technology shows unmatched efficacy in solid tumors
• U.S. Phase I trial: 80% ORR in high-dose group for late-stage colorectal cancer
• First CAR-T to show significant activity in solid tumors, a 91% share of cancer mortality
• Scalable to other cancers including prostate, pancreatic, and thyroid
• U.S. IND approved, Fast Track designation granted, and Nasdaq IPO planned
Market Opportunity:
• Colorectal cancer: 550K new cases annually in China, 155K in the U.S. • Unmet need for effective third-line treatment options in metastatic cases • Potential $4B+ revenue if just 20% of late-stage U.S. patients are treated
• Colorectal cancer: 550K new cases annually in China, 155K in the U.S. • Unmet need for effective third-line treatment options in metastatic cases • Potential $4B+ revenue if just 20% of late-stage U.S. patients are treated
Problem & Solution
• Problem: Existing CAR-T therapies are ineffective in solid tumors due to antigen inaccessibility
• Solution: Dual CAR-T mechanism where CD19 activation triggers solid tumor-targeted T-cell expansion, improving infiltration and tumor-killing
Highlights
• U.S. IND approved for colorectal cancer product (GCC19CART)
• Fast Track status from FDA granted
• Completed Phase I clinical trial with ORR up to 80%
• Over 25 honors and awards in biotech innovation and clinical excellence
• Ongoing global expansion with Phase II and IPO planned in 2025
Exit Strategy
• Nasdaq IPO planned
• Potential acquisition by global pharma leaders
• Licensing deals or joint ventures with multinational drug makers
Apply to Join
Applications are reviewed by the GlobalReach coordination team. Only shortlisted experts will be contacted (NDA for documents).
Sign in may be required before submission.
